Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed DCIS by breast core biopsy with a corresponding lesion on breast MRI of at least 1-cm3 in volume.~* Patients may have undergone treatment with prior chemotherapy if this was greater than 12 months prior to current diagnosis.~* Age \>18 years.~* ECOG performance status \<2 (Karnofsky \>60%)~* Life expectancy of greater than 12 months.~* Normal organ and marrow function as defined below:~* leukocytes \>3,000/mcL~* absolute neutrophil count \>1,500/mcL~* platelets \>100,000/mcL~* total bilirubin within normal institutional limits~* AST(SGOT) \& ALT(SGPT)within normal institutional limits~* creatinine \<1.5 times institutional upper limit of normal or creatinine clearance \>60 mL/min/1.73 m2~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Pregnancy~* Patients who have undergone prior excisional biopsy for DCIS.~* Patients who are unable to undergo MRI due to claustrophobia or other reason.~* Patients with ipsilateral treatment for DCIS or breast cancer within 12 months prior to entering this study.~* Patients receiving any other chemotherapy or investigational agents.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extracts or sensitivity to green tea.~* Uncontrolled concurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Women with Ductal Carcinoma in Situ (Type: EXPERIMENTAL): Women who have been diagnosed with ductal carcinoma in situ (DCIS) and will be taking Polyphenon E

Based on this trial design, predict the completion outcome and termination type (if applicable).